COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,388 Articles (22,816 medRxiv, 8,572 bioRxiv)

Most recent first Previous |  Page 1095: Articles 10941-10950  | Next

A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection.
Coria, L. M., Saposnik, L. M., Pueblas Castro, C., Castro, E. F., Bruno, L. A., Stone, W. B., Perez, P. S., Darriba, M. L., Chemes, L. B., Alcain, J., Mazzitelli, I., Varese, A., Salvatori, M., Auguste, A. J., Alvarez, D. E., Pasquevich, K. A., Cassataro, J.
10.1101/2021.12.07.471590 — Posted: 2021-12-09
Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
Walls, A. C., Sprouse, K. R., Joshi, A., Bowen, J. E., Franko, N., Navarro, M.-J., Stewart, C., McCallum, M., Goecker, E. A., Degli-Angeli, E. J., Logue, J., Greninger, A., Veesler, D.
10.1101/2021.12.08.471707 — Posted: 2021-12-09
Vaccine hesitancy for COVID-19 explored in a phenomic study of 259 socio-cognitive-behavioural measures in the UK-REACH study of 12,431 UK healthcare workers
McManus, C., Woolf, W., Martin, C. A., Nellums, L. B., Guyatt, A. L., Melbourne, C., Bryant, L., Gupta, A., John, C., Tobin, M. D., Carr, S., Simpson, S., Gregary, B., Aujayeb, A., Zingwe, S., Reza, R., Gray, L. J., Khunti, K., Pareek, M.
10.1101/2021.12.08.21267421 — Posted: 2021-12-09
Trust in the research community predicts intent to comply with COVID-19 prevention measures: An analysis of a large-scale international survey dataset
Han, H.
10.1101/2021.12.08.21267486 — Posted: 2021-12-09
First and Second Wave Dynamics of Emergency Department Utilization during the COVID-19 Pandemic: a retrospective study
Dijk, R., Plaum, P., Tummers, S., van Osch, F., Barten, D., Latten, G.
10.1101/2021.12.09.21267520 — Posted: 2021-12-09
Structural Insights of SARS-CoV-2 Spike Protein from Delta and Omicron Variants
Sadek, A., Zaha, D., Ahmed, M. S.
10.1101/2021.12.08.471777 — Posted: 2021-12-09
A Graph Convolutional Network-based screening strategy for rapid identification of SARS-CoV-2 cell-entry inhibitors
Gao, P., Xu, M., Zhang, Q., Chen, C., Guo, H., Ye, Y., Zheng, W., Shen, M.
10.1101/2021.12.08.471787 — Posted: 2021-12-09
Mutations in the spike RBD of SARS-CoV-2 omicron variant may increase infectivity without dramatically altering the efficacy of current multi-dosage vaccinations
Li, B., Luo, X., McAndrews, K. M., Kalluri, R.
10.1101/2021.12.08.471688 — Posted: 2021-12-09
Deep Mutational Engineering of broadly-neutralizing and picomolar affinity nanobodies to accommodate SARS-CoV-1 & 2 antigenic polymorphism
Laroche, A., Orsini Delgado, M. L., Cuniasse, P., Dubois, S., Sierocki, R., Gallais, F., Debroas, S., Bellanger, L., Simon, S., Maillere, B., Nozach, H.
10.1101/2021.12.07.471597 — Posted: 2021-12-09
Orally administered epeleuton inhibits SARS-CoV-2 viral load, replication and pathology in the Syrian Hamster model
Climax, J., Hamza, M., Lafferty, A., Guilfoyle, K., van Amerongen, G., Stadler, K., Wohlsein, P., Baumgärtner, W., Weissbach, M., Coughlan, D.
10.1101/2021.12.07.471588 — Posted: 2021-12-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).